Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) announced that recently, the company and its subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration (“State Drug Administration”) to issue the “Drug Clinical Trial Approval Notice” for SHR-4375 injections, adbelizumab injections, SHR-8068 injections, bevacizumab injections, HRS-4642 injections, and SHR-9839 (sc) for injection. testing.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) announced that recently, the company and its subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration (“State Drug Administration”) to issue the “Drug Clinical Trial Approval Notice” for SHR-4375 injections, adbelizumab injections, SHR-8068 injections, bevacizumab injections, HRS-4642 injections, and SHR-9839 (sc) for injection. testing.